Epoetins and mortality in patients with cancer.

摘要

Julia Bohlius and colleagues1 report increased mortality in cancer patients treated with recombinant human erythropoiesis-stimulating agents (ESA). The results are not surprising, considering that red-cell transfusion can decrease survival in critically ill patients.